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Nuclear hormone receptors are cytoplasm-based transcription factors that bind
a ligand, translate to the nucleus and initiate gene transcription in complex with
a co-activator such as TIF2 (transcriptional intermediary factor 2). For structural
studies the co-activator is usually mimicked by a peptide of circa 13 residues,
which for the largest part forms an -helix when bound to the receptor. The aim
was to co-crystallize the glucocorticoid receptor in complex with a ligand and the
TIF2 co-activator peptide. The 1.82 A˚ resolution diffraction data obtained from
the crystal could not be phased by molecular replacement using the known
receptor structures. HPLC analysis of the crystals revealed the absence of the
receptor and indicated that only the co-activator peptide was present. The self-
rotation function displayed 13-fold rotational symmetry, which initiated an
exhaustive but unsuccessful molecular-replacement approach using motifs
of 13-fold symmetry such as - and -barrels in various geometries. The
structure was ultimately determined by using a single -helix and the software
ARCIMBOLDO, which assembles fragments placed by PHASER before using
them as seeds for density modification model building in SHELXE. Systematic
variation of the helix length revealed upper and lower size limits for successful
structure determination. A beautiful but unanticipated structure was obtained
that forms superhelices with left-handed twist throughout the crystal, stabilized
by ligand interactions. Together with the increasing diversity of structural
elements in the Protein Data Bank the results from TIF2 confirm the potential
of fragment-based molecular replacement to significantly accelerate the phasing
step for native diffraction data at around 2 A˚ resolution.
1. Introduction
Nuclear hormone receptors constitute a superfamily of ligand-
activated transcription factors that includes the mineralo-
corticoid receptor, oestrogen receptor, progesterone receptor,
androgen receptor, vitamin D receptor, thyroid hormone
receptor, peroxisome proliferator-activated receptors and
glucocorticoid receptor (GR). Together with progesterone
receptor, androgen receptor and mineralocorticoid receptor,
GR belongs to the oxosteroid hormone receptor family. Upon
binding of a steroid ligand such as cortisol, prednisolone or
dexamethasone, GR detaches from its cytosolic complex with
the chaperone HSP90, dimerizes and translocates into the
nucleus where it interacts with a co-regulator. Depending on
whether transcription is activated or repressed, the co-
regulator can be TIF2 (transcriptional intermediary factor 2)
or NCoR (nuclear receptor co-repressor). Genes regulated by
GR are involved in sugar metabolism, cell differentiation,
‡
inflammation and immunosuppression (Newton, 2000). For
example, the GR ligand dexamethasone has been used for
decades as an anti-inflammatory and immunosuppressant
and is listed by the World Health Organization as an
essential medicine (http://www.who.int/medicines/publications/
essentialmedicines). GR is also a potential drug target for
diabetes (Jacobson et al., 2005), rheumatoid arthritis (Laan et
al., 1999), allergic diseases (Barnes, 1999) and leukaemia
(Renner et al., 2003). For structure-based drug design, it is
sufficient to consider the ligand-binding domain (Wurtz et al.,
1996) of GR in complex with a small part of the co-regulator,
usually a peptide of nine to 15 residues that for the most part
forms an -helix when bound to GR (Fig. 1).
During the GR drug-design program a crystal was obtained
that could not be phased by any of the known structures of GR
(Bledsoe et al., 2002; Kauppi et al., 2003; Biggadike et al., 2008,
2009; Madauss et al., 2008; Suino-Powell et al., 2008; Schoch et
al., 2010; Seitz et al., 2010; Carson et al., 2014; He et al., 2014;
Edman et al., 2014), indicating that GR was not part of the
crystal. Analysis of the crystal confirmed the absence of GR
and the presence of the co-activator peptide TIF2 only. The
diffraction data revealed intriguing 13-fold rotational
symmetry, leading to the generation of a number of trial
models for molecular replacement, all of which ultimately
turned out to be wrong. Using an ideal -helix as the search
model, the recently deployed ARCIMBOLDO software
(Sammito et al., 2014; Milla´n et al., 2015) in its ‘lite’ version –
which is easy to install on a single workstation and which does
not need setup of a scheduling grid – was able to successfully
pre-assemble partial solutions from PHASER (McCoy et al.,
2007) such that they could be used for density modification
and chain tracing in SHELXE (Sheldrick, 2010). The minimal
model requirements for structure determination are reported,
including the fact that a slightly too long or too short helix will
result in failure. Marked differences in helix length are
apparent when comparing the structures of the co-activator
peptide bound to GR and in the tridecameric assembly. The
TIF2 problem is captivating crystallographically and the
success in structure determination using minimal prior infor-
mation instils hope that other enigmatic data sets corre-
sponding to unanticipated structures can be phased using
similar approaches.
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Figure 1
Structure of GR. The receptor (PDB entry 3mnp, Seitz et al., 2010; grey
ribbon) is an all-helical protein with a central solvent-excluded ligand-
binding cavity and a lateral surface binding site for the co-activator. The
steroid ligand and co-activator peptide TIF2 are coloured yellow and
dark green, respectively. There are no direct contacts between the two
molecules. The sequence of the co-activator peptide visible in this
structure is NALLRYLLD.
Table 1
Data collection and refinement statistics for 4wg0.
Unless noted otherwise, values in parentheses correspond to the highest
resolution shell.
Data collection
Wavelength (A˚) 0.9722
Resolution range (A˚) 45.2–1.82 (1.89–1.82)
100% criterion (A˚)† 1.85
Range/increment () 245/1.0
Mosaicity () 0.69  0.14
Space group C2
Cell dimensions (A˚,) a = 95.9, b = 37.8, c = 101.4,
 = 96.8
Total reflections 131943 (11128)
Unique reflections 32046 (3053)
Multiplicity 4.1 (3.6)
Completeness (%) 97.5 (93.1)
Rmerge/Rmeas‡ 0.05/0.06
CC1/2/CC*‡ 0.999 (0.852)/1 (0.959)
Average I/(I) 15.1 (3.0)
Wilson B (A˚2) 25.4
h|E2 1|i‡§ 0.784 (0.736/0.541)
Mean hL2i‡§ 0.352 (0.333/0.200)
Refinement
Resolution range (A˚) 45.2–1.82 (1.89–1.82)
No. of work reflections 32008 (2621)
No. of test reflections 1605 (136)
Rcryst (%)} 18.5 (25.5)
Rfree (%)} 21.8 (29.0)
No. atoms: non-H, peptide, ligands†† 2177, 1491, 559
No. residues: peptide, H2O, SO
2
4 , CHD‡‡ 169, 127, 24, 13
Coordinate/phase errors (A˚/)§§ 0.18/23.3
R.m.s.d. bonds/angles (A˚/)§§ 0.012/1.52
Ramachandran plot (%)}} 98.2/1.2/0.6
MolProbity/clashscore 1.91/6.0
hBi (A˚2): protein, H2O, SO24 , CHD 45, 42, 82, 50
† The 100% criterion was calculated using SFTOOLS (Winn et al., 2011) and represents
the resolution in A˚ of a 100% complete hypothetical data set with the same number of
reflections as the measured data. ‡ E values, L values (for acentric reflections) and R
factors were calculated using PHENIX (Zwart et al., 2008). R values and the correlation
coefficients CC1/2 and CC* are defined in Diederichs & Karplus (1997) and Karplus &
Diederichs (2012), respectively. § Values in parentheses are the expected values for
untwinned and perfectly twinned data, respectively. } Rcryst =
P jjFoj  jFcjj=
P jFoj,
where Fo and Fc are the structure-factor amplitudes from the data and the model,
respectively. Rfree is Rcryst with 5% of test set structure factors. †† Ligands are sulfate
and cholic acid. ‡‡ Chains A and B have only one SO24 associated with
them. §§ Calculated using PHENIX (Zwart et al., 2008). }} Calculated using COOT
(Emsley et al., 2010). Numbers reflect the percentage of amino-acid residues in the core,
allowed and disallowed regions, respectively. The ill-fitting residue is Lys12 of chain K,
which has poor electron density. MolProbity score should approach the high
resolution limit (Chen et al., 2010). Clashscore is defined as the number of unfavourable
all-atom steric overlaps  0.4 A˚ per 1000 atoms (Word et al., 1999).
2. Materials and methods
2.1. Peptide and protein preparation
Human GR was prepared as described previously (Schoch
et al., 2010). The final concentration prior to crystallization was
16 mg ml1 in 50 mM Tris–HCl pH 7.5, 10% glycerol, 0.3M
NaCl, 2 mM TCEP, 0.5% of the cholic acid derivative CHAPS
(equivalent to 80 mM). The co-activator peptide is derived
from TIF2 and was synthesized as acetyl-KENALL-
RYLLDKD-CONH2, i.e. with the N-terminus acetylated and
the C-terminus amidated (molecular weight 1632 g mol1).
The electron density later confirmed that this sequence is
wrong and the first two residues KE of the peptide are in fact
EK.
2.2. Crystallization, crystal analysis and data collection
20 ml of 11 mM TIF2 in 50 mM Tris–HCl pH 7.5 was mixed
with 200 ml of 16 mg ml1 GR and set up for sitting-drop
vapour-diffusion crystallization at 295 K. Complex and reser-
voir were mixed in a 1:1 ratio with 1–2 ml drop volume.
Crystals were obtained from 2M (NH4)2SO4, 5–10% glycerol,
0.1M citric acid pH 3.5 and were analysed by HPLC in H2O +
0.1% TFA (trifluoroacetic acid) on a Poroshell 300SB-C8
(Agilent) using a 10–70% linear gradient to acetonitrile +
0.08% TFA over 4 min at 1 ml min1 flow rate. The signal was
monitored at 214.4 nm, i.e. at the backbone amide absorption.
Crystals were cryo-protected with 16% glycerol, 1.6M
(NH4)2SO4, 80 mM citric acid pH 3.5. Diffraction data were
collected at 100 K on beamline PX-II at the Swiss Light
Source using a MAR CCD 225 detector, and integrated and
scaled in space group C2 withDENZO (Otwinowski & Minor,
1997) and SADABS (Bruker), respectively (Table 1).
Assuming one GR/TIF2 complex in the asymmetric unit the
Matthews coefficient (Matthews, 1968) is 2.5 A˚3 Da1. After
structure determination the true Matthews coefficient turned
out to be 2.8 A˚3 Da1 (33 kDa molecular weight, including H
atoms, ligands, water and sulfates) with a solvent content of
55.6%. No anomalous information that could have helped in
phasing was detected in the data as judged by analysis with
XPREP (Bruker). Patterson maps and rotation functions were
calculated with FFT and POLARRFN, respectively (Winn et
al., 2011). Model building was done with COOT (Emsley et al.,
2010) and figures were drawn with PyMOL (Schro¨dinger).
3. Results
None of our previously determined mouse (Seitz et al., 2010)
and human GR structures (Schoch et al., 2010) could be used
to phase the diffraction data. Since nuclear receptors are
known to exhibit large conformational changes (Veleiro et al.,
2010), a selenomethionine-modified GR was prepared in
order to obtain experimental phases. However, the crystals did
not exhibit the expected fluorescence excitation for selenium
(data not shown), which raised the first suspicion that the
receptor might not even be part of the crystals. Native crystals
were washed and subjected to mass spectrometry, which
confirmed the presence of TIF2, but no GR was detected (data
not shown). To exclude the possibility of inefficient ionization
of GR in the mass spectrometer, HPLC as an independent
method was performed on washed crystals (Fig. 2) and
compared to the elution properties of the putative constitu-
ents GR and TIF2. The HPLC analysis confirmed the absence
of GR and only TIF2 was detected in the crystals. These
observations are also in accord with the absence of UV-
induced fluorescence in the crystals as only GR but not TIF2
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Figure 2
HPLC analysis of the supposed GR/TIF2 complex crystals reveals the
presence of TIF2 peptide only. The top panel establishes that TIF2 elutes
at 1.3 min. The middle panel is a mixture of TIF2 peptide and GR as used
for crystallization. The largest peak at 2.7 min is GR. The peak at 2.4 min
is an unknown compound, probably a contaminant as it also appeared in
the bottom panel and in blank runs (not shown). The bottom panel
represents the washed crystals. As no GR is present, the crystals only
contain TIF2 peptide. Other signals may belong to crystallization buffer
components that have not been washed away.
contains tryptophan. The volume of the C2 asymmetric unit is
large enough to host up to 22 peptide molecules of 1.6 kDa at
a Matthews coefficient of 2.5 A˚3 Da1. A large number of
molecules would probably render structure determination
somewhat difficult, even if the structure of the motif were
known. Indeed, initial attempts to use the TIF2 structure from
previously determined GR complexes, a short -helix of nine
to ten residues (Fig. 1), as a search model in PHASER did not
yield a solution that was interpretable by eye or that could be
extended into an interpretable map by SHELXE.
3.1. Search models in accord with the self-rotation function
If the crystals contain several copies of a small motif, some
type of non-crystallographic symmetry (NCS) would have
been expected. Apart from the crystallographic peak arising
from C-centring, the Patterson function (Patterson, 1935) was
featureless, which excludes translational NCS. By contrast, a
self-rotation function analysis revealed the presence of a 13-
fold rotational NCS (see Fig. 3 and the movie in the supporting
information), which is consistent with 13 entities arranged in a
ring-like structure. The corresponding Matthews coefficient
would be rather large, 4.3 A˚3 Da1, if the crystal were
composed of the 1.6 kDa TIF2 peptide only. Because the
diffraction data extend to a resolution of 1.82 A˚ (Table 1), the
crystal should be packed rather tightly, indicating that either
another component is part of the 13-fold entity or there is
scattering mass that does not exhibit 13-fold symmetry.
The 13-fold NCS inspired the construction of search models
for molecular replacement of the same symmetry. The ring-
like shape of the 13-mer indicated by the self-rotation function
could possibly be a planar barrel. In case there was a trans-
lational component (for which the self-rotation is insensitive)
this translation must not result in a pseudo-translational NCS
because the Patterson function does not support it (see
above). Such a barrel would have to have its constituents
parallel to each other since only even-numbered barrels can
have an entirely anti-parallel arrangement. The termini in a
parallel barrel are aligned, an unlikely situation for a charged
peptide. However, as the TIF2 peptide is N-terminally
acetylated and C-terminally amidated, no Coulomb repulsion
is present and a parallel arrangement is possible. Short
peptides in solution cannot be assumed to fold into the
structures they adopt when bound to a larger protein, so any
regular arrangement of the peptide with a 13-fold symmetry is
a possibility. Peptides have been observed to form -type fibril
structures (Smith, 2012; Tycko &Wickner, 2013) and there is a
multitude of parallel -barrel substructures with different
radii and tilt angles in the PDB (Protein Data Bank) that have
up to 39 strands in the major vault protein (Casan˜as et al.,
2013). A model for a tridecameric parallel -barrel was
constructed and, when aligned with the NCS axis, it roughly
reproduces the self-rotation function of the diffraction data
(Fig. 4a). Although the similarity between the self-rotation
function sections is less than hoped for, we constructed 6480
barrels with varying radii (11–19 A˚), strand rotations (0–355,
even if this meant breaking hydrogen bonds) and tilt angles
(0–45). All models failed to result in a molecular-replacement
solution based on negative log-likelihood gains in PHASER,
which essentially means that they performed worse than a
random assortment of atoms.
Analysis of the Wilson plot (Morris et al., 2004) for
secondary-structure content (Popov et al., personal commu-
nication) suggested a high -helical content of the structure
(55 15%), while the content of -strands was predicted to be
low (circa 10  10%). Thus, -helical barrel structures were
tested next as possible models for molecular replacement.
Such barrels produce similar self-rotations (Fig. 4b) albeit with
more symmetry elements present compared to the diffraction
data (Fig. 3a). The Crick parameters for -helical barrels
(Crick, 1953) were used to generate a few hundred parallel
tridecameric barrels of various radii and helix tilt angles
[program provided by J. Holton using the formulation from
Harbury et al. (1995)] for molecular-replacement searches.
This approach was successful previously in the structure
determination of the four-stranded coiled-coil A-domain of
the voltage-gated potassium channel Kv7.4 (Howard et al.,
2007). -Helical barrels are usually not as wide as -barrels,
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Figure 3
Self-rotation function analysis of the diffraction data. (a) The stereo-
graphic projection of the  = 180 section of the self-rotation function
calculated at 1.82 A˚ resolution in space group C2 was plotted at a contour
level of 40% of the origin peak. The crystallographic twofold axis is at ! =
90, ’ = 90. Six additional twofold axes are visible which form a crescent.
(b) Signal of a recurrent peak at ! = 40, ’ = 0 as a function of  that is
not visible in (a). The peaks follow the term (n 360)/13 with the integer
n  6, indicating 13-fold NCS. Combination of this axis with the
crystallographic twofold axis leads to the twofold NCS axes visible in (a).
unless they are part of a larger assembly. For example, the
ATP synthase rotor ring (PDB entry 2x2v, Preiss et al., 2010)
has 13-fold symmetry with two nested barrels of different
diameter. After none of the barrels resulted in a molecular-
replacement solution, it was realized that a single -helix also
exhibits 13-fold internal symmetry: the 3.613-helix has 13
atoms in a hydrogen-bonded ring as the repeating pattern.
Alignment of a single -helix with the NCS axis in the crystal
setting of the data produces similar features in the self-
rotation function compared to the diffraction data (not
shown). However, the cell volume is too large to host just a
single long -helix, and several parallel helices should have
manifested as a repeating pattern in the self-Patterson map,
similar to what is observed with DNA (Egli et al., 2007).
At this point, although the scattering mass of the search
model was <10% of the asymmetric unit, PHASERmolecular-
replacement searches for 13 copies of a single -helix in any
orientation were started with ideal -helices of varying
lengths. Although a solution with a high LLG (log-likelihood
gain) value of 443 was obtained for a search with a decamer
helix and the model did not exhibit excessive clashes, the
electron-density maps were uninterpretable and did not
improve after density modification with SHELXE. Expert
handling of the programs’ parameters might have resulted in a
more favourable outcome, but in our hands, the ARCIM-
BOLDO approach described in the following was straight-
forward.
3.2. Structure determination with ARCIMBOLDO and model
requirements
ARCIMBOLDO (Rodrı´guez et al., 2009; Sammito et al.,
2014) is a program that combines the programs PHASER and
SHELXE. Originally intended for ab initio phasing at atomic
resolution (1.2 A˚ or better), accurate secondary-structure
fragments such as ideal polyalanine -helices can be placed
using PHASER and are then selected and pre-assembled as
starting coordinates for several cycles of automated chain
tracing after density modification in SHELXE.
A structure is possibly determined if the SHELXE map
correlation coefficient (CC) exceeds 25%, although the
threshold depends on the resolution and presence of transla-
tional NCS. The ‘lite’ version of ARCIMBOLDO was used on
a computer with 16 Intel Xeon CPUs (E5-2670, eight cores @
2.60 GHz) and with 132 GB RAM running CENTOS 6.5 to
yield a traced (98 residues) solution within an hour using an
ideal polyalanine -helix of ten residues and all B values set to
30 A˚2 as the initial model (Fig. 4c). The model requirements
for success were then systematically tested by varying the helix
length and the number of molecules that were searched for
(Fig. 5). Interestingly, there are sharp boundaries between
success and failure. The smallest ideal helix that can yield a
solution (five residues was the lower limit tested) is eight
residues when at least two molecules are searched for in
PHASER. The resulting CC is 36%. The same conditions
apply to a nonamer helix, but for helices of seven or less
residues no solution was obtained, even if eight molecules
were searched for in PHASER (12 h CPU time). On the other
hand, helices with ten or 11 residues require only a single copy
to be found in order to enable chain tracing in SHELXE,
which corresponds to 3.5% and 3.8% of the total peptide
scattering mass (1443 atoms). Helices of 12 and more residues
fail to produce a solution, both with and without using packing
considerations as a rejection criterion for model placement.
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Figure 4
Stereographic projections of the  = 180 section of the self-rotation
functions from (a) a 13-mer parallel -barrel, (b) a tridecameric -barrel
from PDB entry 2x2v and (c) the refined superhelical TIF2 structure. The
molecules in (a) and (b) were aligned with the NCS axis at ! = 40, ’ = 0
to facilitate comparison with the diffraction data (Fig. 3a) and the final
model in (c). The regular barrels have more internal symmetry elements
than the true structure. Of note is the presence of the 13-fold NCS axis in
this  section, but its absence in the correct structure in (c). Calculations
were done as in Fig. 3(a) except that for the representations (a) and (b)
the initial contour levels were raised to 90% and 70% of the C2
crystallographic peak in order to better visualize the twofold axes.
Taken together there is both a lower and an upper limit for a
suitable search model. Because a single residue can make the
difference between success and failure, varying the size of the
molecular fragment that is used in ARCIMBOLDO may
prove useful for other cases, computing power permitting.
Interestingly, a single helix from the refined structure is a valid
search model without invokingARCIMBOLDO, but the TIF2
peptide from other GR/TIF2 complexes truncated to eight,
nine or ten residues is not. The main-chain atom r.m.s.d. (root
mean square distance) between these TIF2 conformations is
0.7 A˚ (see below for conformational differences), placing a
lower limit for model precision in this case. The main-chain
atom r.m.s.d.s of the 13 refined TIF2 chains differ from an
ideal helix by only 0.38  0.03A˚, indicating that somewhere
between 0.4 and 0.7 A˚ r.m.s.d. between the coordinates of the
search model and the true structure a molecular replacement
will be successful.
The strategy underlying ARCIMBOLDO is to locate a
partial, yet very accurate, substructure and expand it through
iterative density modification and autotracing. Previous
experiences with SHELXE expansion (Thorn & Sheldrick,
2013) have shown that a large penalty is paid for incorrect
parts in this substructure. Much better results are obtained
with a smaller, error-free model than for a more complete but
inaccurate model. In other words, the search for a good partial
substructure followed by expansion of such solutions with
SHELXE may be superior to an attempt to generate a
complete model by placing all 13 helices first and then running
density modification and autotracing. In addition, correct
partial solutions may be discarded by the packing test if the
next copy is incorrectly placed. After placement of each new
fragment, an initial CC (Fujinaga & Read, 1987) is calculated
and optimized by sequentially omitting every amino acid in
the partial model and eliminating them if this leads to CC
improvement (Sheldrick & Gould, 1995). Models are scored
after this so-called omit CC and a number of partial structures
equal to the number of physical cores in the computer minus
one are sent to expansion. For the TIF2 case, even in a search
for six helices the best solution was already reached with a
substructure obtained after placement of only four fragments
(see Fig. S2 in the supporting information).
3.3. TIF2 forms a superhelix with a left-handed twist
Placement of the 13 TIF2 helices into closest proximity
revealed their arrangement as a superhelix of outer diameter
42  46 A˚. The superhelix has a left-handed twist and is
extended by crystallographic symmetry, hence traversing the
crystal (Fig. 6a). The height of a single turn is 66 A˚ with 13
repeats per turn. The projection of the asymmetric unit along
the NCS axis is a barrel (Fig. 6b), albeit very different
compared to the parallel -helical barrels considered above.
The helices are not arranged parallel to each other but are
organized in pairs which point their C-termini towards each
other and the N-termini are located on the surface of the
superhelix (Fig. 6). This non-parallel arrangement of proto-
mers may contribute to the absence of self-Patterson peaks
and would have been difficult to anticipate from NCS analyses.
The repeating unit in the superhelix is thus a pair of -helices,
one of which is shared by two individual turns. There are two
pairs of leucine residues in the TIF2 sequence, Leu5/6 and
Leu9/10, which interlace to form a continuous hydrophobic
core in the superhelix (grey sticks in Figs. 6b and 6c). A
similarly extended hydrophobic core is present in the packing
of the P22 tailspike adhesin -helix (Simkovsky & King, 2006),
in armadillo repeats (Reichen et al., 2014) and in amyloid-
structures (Colletier et al., 2011). Together with a cholic acid
ligand interaction (see below) this interdigitation of aliphatic
residues seems to be the driving force for generating the TIF2
superhelix. The individual helices are quite similar to each
other and superimpose with r.m.s.d. values of 0.12  0.03 A˚
and 0.22  0.06 A˚, respectively, for secondary-structure
matching of the main-chain atoms and for least-squares
matching of all atoms including side chains (Fig. 7a). A central
core of eight residues (NALLRYLL) is almost invariant
among the protomers. The largest conformational differences
are seen in the two C-terminal residues, which deviate from
ideal -helical geometry, the tips of the Glu1 and Arg7 side
chains, and the carboxylate group of cholic acid (see below).
Two sulfate ions are present per protomer; one is located close
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Figure 5
Length requirements for the ideal polyalanine -helix search model.
Helices between five and 14 residues were used as models, and one to
eight copies were searched for in PHASER, followed by three cycles of
density modification and automated polyalanine chain tracing in
SHELXE. All calculations were done at the maximum resolution of
1.82 A˚. The solvent content was set to 0.65, slightly higher than expected
in order to help solvent flattening, and in the auto-tracing -helices were
searched for in all cycles (-q option). The NCS option in SHELXE is
available for substructures but not for tracing and hence was not
applicable here. Helices between eight and 11 residues are suitable search
models as judged by CC > 25%. The most extensive search performed
was for nine fragments of a decamer helix, which yielded a final LLG of
576. For improved legibility the data points (black spheres) are projected
onto the grey walls of the plot (blue and white dots).
to the N-terminus and neutralizes the helix dipole, and the
other is bound to the guanidinium side chain of Arg7. The
acetyl group at the N-terminus of the TIF2 peptide continues
the helical hydrogen-bonding pattern, effectively serving as a
helix cap (Fig. 7a).
3.4. TIF2 has different conformations when bound to GR or
when assembled into a superhelix
When bound to GR the TIF2 sequence NALLRYLL forms
an eight-residue -helix with frayed ends. In contrast, when
crystallized alone the TIF2 peptide forms an -helix over its
entire length less the C-terminal aspartyl amide, but including
the N-terminal acetyl group. The two TIF2 conformations
superimpose with a main-chain atom r.m.s.d. of 0.7 A˚ and have
their N-termini 4.5 A˚ away from each other (spheres in Fig.
7b). The conformation of TIF2 that is present in the superhelix
would clash with residues from GR, explaining why the helix
of the co-activator peptide must be shorter when bound to the
receptor. There is currently no crystal structure available for
the entire co-activator (the entire TIF2 has 1464 residues) or a
structural domain encompassing the TIF2 motif that recog-
nizes GR. Thus, at present it cannot be determined whether
the co-activator helix has to partially melt in order to bind to
GR or whether its conformation in the context of the co-
activator is already the same as that seen in the GR/TIF2
complex.
3.5. The TIF2 superhelix is stabilized by a steroid ligand
The high quality of the SHELXE electron density allowed
detection of an error in the TIF2 peptide sequence used for
crystallization (Fig. 8). The first two residues are swapped,
possibly due to a typo that occurred when the peptide
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Figure 6
Superhelical TIF2 structure and packing in the C2 unit cell. (a) The C2 unit cell is shown in cross-eyed stereo as a grey box with the origin at the bottom
right and its four asymmetric units. One asymmetric unit consists of 13 short helices of the TIF2 peptide (coloured cylinders) that are arranged around
the NCS axis, which is shown as a red line. Another asymmetric unit centred on the NCS axis is shown in grey with space-filling models (green) of the
cholic acid molecules that wedge between the helices. The asymmetric units combine to form a continuous left-handed superhelix that traverses the
crystal, which is well visible through a surface representation of three individually coloured asymmetric units. The fourth asymmetric unit is coloured
blue and the N-termini of the helices are marked by a sphere, showing that the arrangement of TIF2 helices is not all parallel as assumed in the models in
Figs. 4(a) and 4(b). The SHELXE-derived electron density is contoured at 1 r.m.s.d. for the whole unit cell. (b) View of the asymmetric unit projected
along the NCS axis with the individual chains labelled. The 14th helix A0 shown in dark blue serves to highlight the repeating pattern in the superhelix.
The N-termini are marked by spheres and point to the outside of the superhelix. Leucine side chains that construct the hydrophobic core are drawn as
grey stick models. (c) View 90 rotated relative to (b).
synthesizer was programmed. In addition, non-proteinaceous
electron density identified a molecule that is wedged between
two adjacent TIF2 helices and that mediates contact between
them by means of hydrogen bonds and van der Waals inter-
actions (Fig. 8). From the SHELXE density alone it was clear
that the ligand is a steroid, which was unanticipated but is
easily explained by the buffer component CHAPS, an amide
of cholic acid. No electron density for the amino part of this
detergent was detected, indicating either disorder or a
hydrolytic event that generated cholic acid. Quantitative mass-
spectrometric analysis of CHAPS revealed the presence of
40 p.p.m. cholic acid, corresponding to 49 mM in the crystal-
lization buffer. Thus, in principle there is enough contam-
inating cholic acid to explain its presence in the crystal
structure. The cholic acid composes about one quarter of the
total scattering mass.
Cholic acid is a convex molecule that fits into a concave
surface patch lined by the methylene groups of Glu1, the side
chains of Ala4 and Leu5, and the aromatic face of the Tyr8
side chain. Connections to the second helix of the sandwich
are made by two hydrogen bonds. A hydroxyl group of the
steroid binds to the carbonyl group of the Asn3 carboxamide,
and the carboxylate of cholic acid engages in a (possibly
charged) hydrogen bond with the guanidinium group of Arg7.
The aliphatic parts of the Leu6, Arg7 and Leu10 side chains
also form a few van der Waals interactions with cholic acid.
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Figure 8
Sandwiching of cholic acid between protomers stabilizes the superhelix. The cross-eyed stereo image shows density-modified but unbiased (i.e. before
building of the cholic acid) electron density at the 2 r.m.s.d. level as a grey mesh. The density for the two N-terminal residues Glu1 and Lys2 reveals the
error in the sequence of the synthetic peptide (red labels). The hydrophobic concave surface into which cholic acid binds is lined by Glu1, Ala4, Leu5 and
Tyr8.
Figure 7
TIF2 conformations in the superhelix and when bound to GR. (a) Superposition of all 13 protomers. The residues are numbered according to the
sequence given at the bottom. The main-chain torsion angles of residues 12 and 13 deviate from -helical geometry. Because of weak electron density,
these residues were modelled with half occupancy. Clashes of these residues with the same residues of neighbouring helices indicate that the crystal
actually contained a mixture of peptides. (b) The GR/dexamethasone/TIF2 complex (Seitz et al., 2010) is superimposed with one representative
protomer (coloured yellow) from the superhelix. GR is coloured grey and the TIF2 peptide in complex with GR is shown in dark green. The N-termini of
the peptides are marked by spheres. The N-terminal part of TIF2 cannot adopt an -helical conformation when binding to GR due to clashes with the
receptor.
The interactions between cholic acid and TIF2 are serendi-
pitous and unlikely to bear biological significance for nuclear
receptor biology. When bound to GR, the ligand and co-
activator peptide do not directly interact (Fig. 1).
4. Discussion
Superhelices are frequently observed in proteins with
sequence repeats. The repeats fold into a small structural
element that can be a small superhelix of either handedness. In
case these structural elements are parallel a ring-shaped
solenoid results, but if successive elements are incrementally
rotated with respect to each other along the superhelical axis,
the solenoid twists and becomes a superhelix (Kobe & Kajava,
2000). Thus, there are two superhelical parameters to be
considered, the superhelicity imposed by the direction of the
polypeptide chain, and the overall twist of the superhelix.
Although these parameters do not seem to depend on each
other, most superhelices are right-handed, both in chain
direction and twist. Examples include the -helical armadillo
repeats (Conti et al., 1998; Huber & Weis, 2001) and tetra-
tricopeptide repeats (Jı´nek et al., 2004; Yuzawa et al., 2011).
The /-structured leucine-rich repeats can also twist into a
right-handed superhelix, as exemplified in the receptor kinase
BRI1 (Hothorn et al., 2011). In contrast, the -helical HEAT
repeats (Cingolani et al., 1999) can induce left- and right-
handed superhelical twists. Currently, the only example of a
left-handed -helical solenoid forming a right-handed super-
helix is the Zurdo domain of human mitochondrial regulator
mTERF (Jime´nez-Mene´ndez et al., 2010). Pronounced left-
handed twists in superhelices are rare and limited to examples
such as the / ankyrin repeats in p53 binding protein (Gorina
& Pavletich, 1996) and the parallel -helix in pectate lyase
(Lietzke et al., 1996). The strong left-handed twist in TIF2
therefore comes as an exception, being the only all -helical
motif that assembles into such a superhelix. The TIF2 peptide
protomers associate in pairs with their N-termini pointing
away from the superhelical axis. Therefore, no pseudo-
solenoid path can be constructed as this requires alternating
N- and C-termini in close proximity. More structures of -
helical peptides are required to denote the rules governing
their superhelical assemblies.
Peptide assemblies are prominent in a number of neuro-
degenerative disorders such as Alzheimer’s disease, Parkin-
son’s disease, spongiform encephalopathies and Huntington’s
disease (Gadad et al., 2011). The aggregates are formed by
peptides that are derived from normal cellular proteins. The
peptides do not share sequence homology but exhibit signifi-
cant flexibility in solution and fold into -type structures,
especially under conditions of low pH, high salt concentration
and high peptide concentration (Murphy, 2002). Superhelical
structures can also be adopted by these peptides. For instance,
the -amyloid peptide 42 forms a superhelix where helical -
sheets wrap around each other (Stroud et al., 2012). The
superhelical structure formed by the TIF2 peptide raises the
possibility that the -helical conformation of peptides can
promote aggregates in vivo as well. While the -amyloid
peptide in Alzheimer’s disease encompasses 42 residues, the
smallest toxic peptide with only 14 residues is the prion
protein PrP 113–126 (Brown, 2000; Murphy, 2002), which is on
the same scale as the TIF2 peptide. In addition, an N-terminal
extension of the PrP 109–122 by five residues changes the
preferred structure from -sheet to -helical (Nguyen et al.,
1995). Thus, small peptides are in principle able to associate
into large stable aggregates of either secondary-structure type.
The TIF2 structure is stabilized by cholic acid, a bile acid
precursor that is also found in cerebrospinal fluid (Ogundare
et al., 2010). Without speculating too much, it is conceivable
that endogenous ligands could stabilize the quaternary struc-
ture of -helical peptide aggregates. In turn, such a stabilizing
small-molecule drug could help inhibit the fibrillation cascade
that leads to -type deposits.
5. Conclusions
For the last two decades, anomalous diffraction methods such
as MAD (multi-wavelength anomalous diffraction), SAD
(single-wavelength anomalous diffraction) and SIRAS (single
isomorphous replacement with anomalous signal) have
contributed the majority of de novo phased structures. In the
absence of anomalous signal, however, direct methods and
molecular replacement remain the only avenues to obtain
phase information, and for most biological samples, direct
methods are out of the question because the crystals do not
diffract to atomic resolution. The data used in this study were
collected in 2006 and could not be phased despite considerable
effort including preparation of selenomethionine-modified
GR (which is absent) and somewhat extensive (and futile)
molecular-replacement searches using models derived from
self-rotation function analyses. During the past eight years,
neither crystals nor starting materials for this project have
been available, so molecular replacement remains the only
viable approach. Software development and Moore’s law
allowed the computationally expensive combination of mole-
cular replacement with chain tracing, which led to facile
structure determination shortly after the release of the
simplified version ARCIMBOLDO_LITE (Milla´n et al.,
2015). We suspect that there are many resilient data sets like
the one discussed here in crystallography laboratories, which
might be phased by molecular replacement. The extension of
the ARCIMBOLDO method from secondary-structure
elements to tertiary structures, either probing fragments from
distant homologues with ARCIMBOLDO_SHREDDER
(Sammito et al., 2014), or using canonic fragments as model
structures with ARCIMBOLDO_BORGES (Sammito et al.,
2013), together with the probably valid assumption that most
macromolecular structural elements are nowadays repre-
sented in the PDB, could significantly speed up the phasing
step provided that native diffraction data to about 2 A˚ reso-
lution are available. To the best of our knowledge, there are
currently 30 previously unknown structures that have been
determined by ARCIMBOLDO methods. The release of the
single-machine implementation ARCIMBOLDO_LITE may
contribute to popularizing this phasing avenue (Rodrı´guez et
research papers
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al., 2012). It could also possibly lead to a shift in the preferred
method to phase unknown structures away from anomalous
data to molecular replacement of native data using small
structural elements, including DNA libraries (Pro¨pper et al.,
2014), as seeds.
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